550 related articles for article (PubMed ID: 10563228)
1. Pathophysiology of migraine--new insights.
Hargreaves RJ; Shepheard SL
Can J Neurol Sci; 1999 Nov; 26 Suppl 3():S12-9. PubMed ID: 10563228
[TBL] [Abstract][Full Text] [Related]
2. New insights into the molecular actions of serotonergic antimigraine drugs.
Durham PL; Russo AF
Pharmacol Ther; 2002; 94(1-2):77-92. PubMed ID: 12191595
[TBL] [Abstract][Full Text] [Related]
3. Lasmiditan mechanism of action - review of a selective 5-HT
Clemow DB; Johnson KW; Hochstetler HM; Ossipov MH; Hake AM; Blumenfeld AM
J Headache Pain; 2020 Jun; 21(1):71. PubMed ID: 32522164
[TBL] [Abstract][Full Text] [Related]
4. Migraine pathophysiology and its clinical implications.
Silberstein SD
Cephalalgia; 2004; 24 Suppl 2():2-7. PubMed ID: 15595988
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of 5-HT7 receptor reduces CGRP release in an experimental model for migraine.
Wang X; Fang Y; Liang J; Yin Z; Miao J; Luo N
Headache; 2010 Apr; 50(4):579-87. PubMed ID: 20236348
[TBL] [Abstract][Full Text] [Related]
6. Serotonin in migraine: theories, animal models and emerging therapies.
Johnson KW; Phebus LA; Cohen ML
Prog Drug Res; 1998; 51():219-44. PubMed ID: 9949863
[TBL] [Abstract][Full Text] [Related]
7. Colocalization of CGRP with 5-HT1B/1D receptors and substance P in trigeminal ganglion neurons in rats.
Ma QP; Hill R; Sirinathsinghji D
Eur J Neurosci; 2001 Jun; 13(11):2099-104. PubMed ID: 11422450
[TBL] [Abstract][Full Text] [Related]
8. [Mechanism of action of zolmitriptan].
Pascual J
Neurologia; 1998 Oct; 13 Suppl 2():9-15. PubMed ID: 9859690
[TBL] [Abstract][Full Text] [Related]
9. The biology of serotonin receptors: focus on migraine pathophysiology and treatment.
Hamel E
Can J Neurol Sci; 1999 Nov; 26 Suppl 3():S2-6. PubMed ID: 10563226
[TBL] [Abstract][Full Text] [Related]
10. Comparison of more and less lipophilic serotonin (5HT1B/1D) agonists in a model of trigeminovascular nociception in cat.
Hoskin KL; Goadsby PJ
Exp Neurol; 1998 Mar; 150(1):45-51. PubMed ID: 9514827
[TBL] [Abstract][Full Text] [Related]
11. Serotonergic mechanisms of trigeminal meningeal nociception: Implications for migraine pain.
Kilinc E; Guerrero-Toro C; Zakharov A; Vitale C; Gubert-Olive M; Koroleva K; Timonina A; Luz LL; Shelukhina I; Giniatullina R; Tore F; Safronov BV; Giniatullin R
Neuropharmacology; 2017 Apr; 116():160-173. PubMed ID: 28025094
[TBL] [Abstract][Full Text] [Related]
12. Preclinical neuropharmacology of naratriptan.
Lambert GA
CNS Drug Rev; 2005; 11(3):289-316. PubMed ID: 16389295
[TBL] [Abstract][Full Text] [Related]
13. Dural vasodilation causes a sensitization of rat caudal trigeminal neurones in vivo that is blocked by a 5-HT1B/1D agonist.
Cumberbatch MJ; Williamson DJ; Mason GS; Hill RG; Hargreaves RJ
Br J Pharmacol; 1999 Mar; 126(6):1478-86. PubMed ID: 10217543
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of action of the 5-HT1B/1D receptor agonists.
Tepper SJ; Rapoport AM; Sheftell FD
Arch Neurol; 2002 Jul; 59(7):1084-8. PubMed ID: 12117355
[TBL] [Abstract][Full Text] [Related]
15. 4991W93 inhibits release of calcitonin gene-related peptide in the cat but only at doses with 5HT(1B/1D) receptor agonist activity?
Knight YE; Edvinsson L; Goadsby PJ
Neuropharmacology; 2001 Mar; 40(4):520-5. PubMed ID: 11249961
[TBL] [Abstract][Full Text] [Related]
16. Basic mechanisms of migraine and its acute treatment.
Edvinsson L; Villalón CM; MaassenVanDenBrink A
Pharmacol Ther; 2012 Dec; 136(3):319-33. PubMed ID: 22939884
[TBL] [Abstract][Full Text] [Related]
17. Is selective 5-HT
Rubio-Beltrán E; Labastida-Ramírez A; Villalón CM; MaassenVanDenBrink A
Pharmacol Ther; 2018 Jun; 186():88-97. PubMed ID: 29352859
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action of serotonin 5-HT1B/D agonists: insights into migraine pathophysiology using rizatriptan.
Goadsby PJ; Hargreaves RJ
Neurology; 2000; 55(9 Suppl 2):S8-14. PubMed ID: 11089513
[TBL] [Abstract][Full Text] [Related]
19. Neurogenic inflammation in the context of migraine.
Williamson DJ; Hargreaves RJ
Microsc Res Tech; 2001 May; 53(3):167-78. PubMed ID: 11301492
[TBL] [Abstract][Full Text] [Related]
20. Migraine: pathophysiology, pharmacology, treatment and future trends.
Villalón CM; Centurión D; Valdivia LF; de Vries P; Saxena PR
Curr Vasc Pharmacol; 2003 Mar; 1(1):71-84. PubMed ID: 15320857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
